Literature DB >> 26165720

On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.

Georges Vauquelin1.   

Abstract

INTRODUCTION: Optimal drug therapy often requires continuing high levels of target occupancy. Besides the traditional pharmacokinetic (PK) contribution thereto, drug-target interactions that comprise successive 'microscopic' steps as well as the intervention of the cell membrane and other 'micro'-anatomical structures nearby may help attaining this objective. AREAS COVERED: This article reviews the 'micro'-pharmacodynamic (PD) and PK mechanisms that may increase a drug's residence time. Special focus is on induced-fit- and bivalent ligand binding models as well as on the ability of the plasma membrane surrounding the target to act as a repository for the drug (e.g., microkinetic model), to actively participate in the binding process (e.g., exosite model) and, along with microanatomical elements like synapses and interstitial spaces, to act on the drug's diffusion properties (reduction in dimensionality and drug-rebinding models). EXPERT OPINION: The PK profile, as well as the target dissociation kinetics of a drug, may fail to account for its long-lasting efficiency in intact tissues and in vivo. This lacuna could potentially be alleviated by incorporating some of the enumerated 'microscopic' mechanisms and, to unveil them, dedicated experiments on sufficiently physiologically relevant biological material like cell monolayers can already be implemented early on in the lead optimization process.

Entities:  

Keywords:  binding mechanisms; diffusion; drug target; membrane; pharmacodynamics; pharmacokinetics; radioligand; rebinding; receptor; residence time

Mesh:

Substances:

Year:  2015        PMID: 26165720     DOI: 10.1517/17460441.2015.1067196

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  14 in total

1.  Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?

Authors:  Christopher T Szlenk; Jeevan B Gc; Senthil Natesan
Journal:  Mol Pharmacol       Date:  2019-04-08       Impact factor: 4.436

Review 2.  Link between a high k on for drug binding and a fast clinical action: to be or not to be?

Authors:  Georges Vauquelin
Journal:  Medchemcomm       Date:  2018-08-16       Impact factor: 3.597

3.  Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

Review 4.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

Review 5.  Ligand binding at the protein-lipid interface: strategic considerations for drug design.

Authors:  Jian Payandeh; Matthew Volgraf
Journal:  Nat Rev Drug Discov       Date:  2021-07-13       Impact factor: 84.694

6.  Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2017-10-18       Impact factor: 8.739

7.  Intracellular rebinding of transition-state analogues provides extended in vivo inhibition lifetimes on human purine nucleoside phosphorylase.

Authors:  Sara T Gebre; Scott A Cameron; Lei Li; Y S Babu; Vern L Schramm
Journal:  J Biol Chem       Date:  2017-08-09       Impact factor: 5.157

8.  Membrane Lipids Are an Integral Part of Transmembrane Allosteric Sites in GPCRs: A Case Study of Cannabinoid CB1 Receptor Bound to a Negative Allosteric Modulator, ORG27569, and Analogs.

Authors:  Peter Obi; Senthil Natesan
Journal:  J Med Chem       Date:  2022-09-06       Impact factor: 8.039

9.  Drug-Target Kinetics in Drug Discovery.

Authors:  Peter J Tonge
Journal:  ACS Chem Neurosci       Date:  2017-07-14       Impact factor: 4.418

10.  Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting β2-Adrenergic Receptor Agonists.

Authors:  Christopher T Szlenk; Jeevan B Gc; Senthil Natesan
Journal:  Mol Pharmacol       Date:  2021-08-01       Impact factor: 4.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.